

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for Information Disclosure Statement (IDS) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/889,287-Conf. #2444
				Filing Date	July 16, 2001
				First Named Inventor	John A. Montgomery
				Art Unit	1623
				Examiner Name	D. Khare
				Attorney Docket Number	21381-00067-US
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
AA	AA	US-5,401,838	03-28-1995	CHOU	
AB	AB	US-5,384,310	01-24-1995	MONTGOMERY et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
BA	BA	WO-92/09604 A1	06-11-1992	BERLEX BIOSCIENCES, INC.		
BB	BB	WO-92/20347 A1	11-26-1992	SOUTHERN RESEARCH INSTITUTE		
BC	BC	EP-0 314 011 A2	05-03-1989	F. HOFFMANN-LA ROCHE & CO.		
BD	BD	WO-89/08658 A1	09-21-1989	SCRIPPS CLINIC AND RESEARCH FOUNDATION		
BE	BE	EP-0 577 303 A1	01-05-1994	ELI LILLY AND COMPANY		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>dkhare</i>	Date Considered	5/10/05
--------------------	---------------	-----------------	---------



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/889,287-Conf. #2444
				Filing Date	July 16, 2001
				First Named Inventor	John A. Montgomery
				Art Unit	1623
				Examiner Name	D. Khare
Sheet	2	of	2	Attorney Docket Number	21381-00067-US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
ML	CA	"Studies on the Azidoazomethine-Tetrazole Equilibrium. V. 2- and 6-Azidopurines" Temple, Jr. et al., Temple, Kussner, and Montgomery, vol. 31 pgs. 2210-2215. February 28, 1966.		
ML	CB	"Correlation of the Proton Magnetic Resonance Chemical Shifts of Substituted Purines with Reactivity Parameters. I. 2,6-Disubstituted Purines", Coburn Jr., et al. Coburn, Thorpe, Montgomery, and Hewson. vol. 30, pgs. 1110-1113. November 16, 1964.		
ML	CC	"Synthesis of 6-Aryloxy- and 6-Arylalkoxy-2-chloropurines and Their Interactions with Purine Nucleoside Phosphorylase from <i>Escherichia coli</i> .", Bzowska et al., J. Biosci. 1999, vol. 54, pgs. 1055-1067.		
ML	CD	"9-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl) guanine: A Metabolically Stable Cytotoxic Analogue of 2'-Deoxyguanosine", Montgomery et al., Journal of Medicinal Chemistry, 1986, 29, 2389, December 23, 1986.		
ML	CE	"Synthesis and Biologic Activity of 2'-Fluoro-2-halo Derivatives of 9-β-D-Arabinofuranosyladenine ¹ ", Montgomery et al., Journal of Medicinal Chemistry 1992, 35, June 17, 1994.		
ML	CF	"Liquid chromatographic study of acid stability of 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, 2-chloro-2'-deoxyadenosine and related analogs", Reichelova et al., J. Pharm. Biomed. Anal. (1995), 13 (4/5), 711-714.		
ML	CG	"Synthesis and Anti-Hepatitis B Virus Activity of 9-(2-Deoxy-2-fluoro-β-L-arabinofuranosyl) purine Nucleosides", Ma et al., J. Med. Chem., 1997, 40, 2750-2754, April 7, 1997.		
ML	CH	"Convergent Syntheses and Cytostatic Properties of 2-chloro-2'-deoxy-2'-fluoroadenosine and its N ⁷ -isomer", Bioorganic & Medicinal Chemistry Letters, Zaitseva, Galina V. et al, vol. 5, No. 24: 2999-3002, 1995, XP00223094: 3300.		
ML	CI	Database CAPLUS on STN (Columbus, OH, USA), No. 122:260176 "Preparative high-performance liquid chromatographic separation of fluorodeoxy sugars", Evangelisto et al. Journal of Chromatography, 1995 695 (1), pages 128-131.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>dkhane</i>	Date Considered	5/10/05
--------------------	---------------	-----------------	---------